Objectives: To describe the prevalence and risk factors for infection due to AmpC b-lactamase-producing Escherichia coli (AmpC-EC).
Introduction
Escherichia coli is a leading pathogen in community, hospitalacquired and healthcare-related infections. 1, 2 An increase in the prevalence of b-lactam resistance, especially concerning the thirdgeneration cephalosporins, has been observed in the last decade, mainly due to the production of ESBLs. 3 -5 Although to a lesser degree, acquired AmpC b-lactamases are also emerging as a potential additional threat to the activity of these antibiotics in many areas. 6 Moreover, as in ESBLs, plasmids carrying genes for AmpC b-lactamases often carry multiple other antimicrobial resistance determinants and there is a substantial risk that the infecting pathogen will be resistant to the empirical antimicrobial therapy used. 7 -9 E. coli AmpC b-lactamases can be chromosome-or plasmidmediated. The E. coli chromosomal bla AmpC gene is transcribed constitutively from a weak promoter and is subject to attenuation. 10, 11 The primary mechanism of AmpC hyperproduction is mutation of the bla AmpC promoter region.
Similar to the chromosomal bla AmpC gene in E. coli, most acquired bla AmpC genes are also expressed constitutively. One exception, among a few others, is the bla DHA-1 gene, which is inducible by b-lactams, and its expression is regulated similarly to that of inducible chromosomal bla AmpC genes present in some Enterobacteriaceae. These genes can be overproduced by derepression in their mechanism of regulation. Hyperproduced AmpC or acquired bla AmpC genes confer resistance to all b-lactams except fourth-generation cephalosporins and carbapenems. Furthermore, the effect of an AmpC b-lactamase in addition to porin mutations of the outer membrane can reduce susceptibility to carbapenems. 12, 13 There are presently no CLSI or other approved criteria for AmpC detection. Only EUCAST has made some recommendations [EUCAST guideline on detection of resistance mechanisms v 1.0 (2013-12-11), http://www.eucast.org/resistance_mechanisms/]. Secondary to the difficulties in their detection in the microbiology laboratory, the epidemiology, risk factors and clinical features associated with infections caused by these organisms have not been well described and there is a paucity of studies on the clinical epidemiology and implications of E. coli harbouring hyperproduced or plasmid-mediated AmpC. 14 -19 The aim of this study was to describe the prevalence and risk factors for infection caused by E. coli harbouring either hyperproduced or plasmid-mediated AmpC b-lactamase.
Methods

Setting and study design
A case-control study was performed in three Spanish hospitals [Hospital Universitari Mú tua Terrassa (HUMT), Hospital de la Santa Creu i Sant Pau (HSCiSP) and Consorci Sanitari de Terrassa (CST)] and their respective primary care centres. Cases were recorded prospectively from June 2010 to November 2011, covering an area with 1 300000 inhabitants. All clinical isolates of E. coli with reduced susceptibility to third-generation cephalosporins from adults recovered in any of these centres were included.
The study was approved by the ethics committees of the participating hospitals. No informed consent was required.
Variables and definitions
Cases were patients with an isolate of an AmpC b-lactamase-producing E. coli (AmpC-EC) causing infection (only one strain per patient). Controls were patients with a cephalosporin-susceptible E. coli isolate, matched 1 : 2 by gender, age and sample origin. Data collected prospectively included patient demographics, comorbidities (Charlson score), 20 severity (defined as the presence of septic shock), the clinical significance of the isolate categorized as infection (when an inflammatory response accompanied by symptoms and/or signs as a consequence of the presence of microorganisms was present), antimicrobial use within the previous 3 months, urinary tract infections in the previous 12 months, urinary and biliary tract abnormalities, indwelling external devices (mechanical ventilation, tracheotomy, urinary catheter, nasogastric tube, nephrostomy, external biliary drainage, endobiliary prosthesis), manipulation of the urinary, biliary, respiratory and/or gastrointestinal tracts within the previous 4 weeks, source of infection and antimicrobial susceptibility pattern of the infecting strain.
Healthcare-related acquisition was defined as a hospital-acquired or healthcare-associated infection. Hospital-acquired infection was defined as an infection acquired during hospital care that was not present or incubating at admission (infections occurring .48 h after admission were considered nosocomial) or in a patient discharged from hospital in the previous 14 days. Healthcare-associated infection was diagnosed if the patient fulfilled at least one of the following criteria: (i) resided in a nursing home or long-term care facility in the 30 days before the episode; (ii) hospitalized in an acute care hospital for ≥48 h ,90 days before the episode; (iii) attended a hospital or haemodialysis clinic or received intravenous therapy ,30 days before the episode; and/or (iv) received intravenous therapy, wound care, enteral nutrition or healthcare at home ,30 days before the episode. Otherwise the infection was considered as community acquired, according to the definitions by Friedman et al. 22, 23 (HSCiSP).
Phenotypic detection of acquired AmpC was performed by using the cefotetan/cefotetan -cloxacillin Etest (bioMérieux) (if deemed appropriate). Visual examination of the antibiogram was carried out to detect colonies in the vicinity of the edge of the haloes of inhibition of cefotaxime, ceftazidime and aztreonam. 24, 25 Molecular detection of acquired bla AmpC genes was done by using the multiplex PCR described by Pérez-Pérez and Hanson. 26 Depending on the outcome of the multiplex, additional primers were used for subsequent amplification and sequencing of the entire gene, as previously described. 27 Hyperproduction of E. coli chromosomal bla AmpC was done by quantitative RT-PCR (qRT-PCR). Alteration of the bla AmpC promoter was studied by PCR, as previously described. 28 Sequencing of the amplified fragments was performed by Macrogen Inc. (Amsterdam, the Netherlands). The different sequences obtained and the deduced amino acid sequences were analysed using the software available online at the network's National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov).
Statistical analysis
Student's t-test was used to compare continuous variables, and the x 2 test or Fisher's exact test was used to compare categorical variables. To determine the independent risk factors for carrying AmpC-EC, all variables with a P value of ,0.05 identified in univariate analyses were subjected to further selection by using forward stepwise (Wald) logistic regression. We used PIN 0.05 and POUT 0.1 as criteria. The SPSS (version 15.0) software package was used for these analyses.
Results
Out of 21 563 isolates of E. coli, 243 (1.1%) had a phenotype that was compatible with the selection criteria. All the isolates were tested with multiplex PCR and by qRT-PCR. Three were found to carry ESBLs and were excluded from the analysis. Eight cases were lost to clinical follow-up and 18 were considered due to colonization. Finally, 214 were included in the analysis. Fourhundred-and-twenty-eight cephalosporin-susceptible E. coli controls were matched.
One-hundred-and-fifty-eight (73.8%) AmpC-ECs were acquired AmpC-producing strains and 56 (26.1%) were AmpC hyperproducers (hAmpCs). No major differences were found between acquired AmpCs and hAmpCs. Among acquired AmpCs, 116 (73.4%) were bla CMYt , all of them CMY-2 except for 1 CMY-4, 1 CMY-7 and 1 CMY-42, and 42 (26.5%) were bla DHAt (all DHA-1) . One strain harboured both DHA-1 and CMY-2. Infections due to DHA-EC producers were more frequently healthcare related and patients with such infections had more comorbidities. No other differences were found in terms of risk factor distribution between EC harbouring DHA or CMY (Table 1) .
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For AmpC-EC-infected patients, the mean age was 71 years and 65% were women. Demographic characteristics, epidemiological features, comorbidities and severity of disease are shown in Table 2 .
Ninety-one cases (42.5%) were strictly community acquired, 34 (15.8%) were strictly hospital acquired and 88 (41.1%) were healthcare associated according to the definitions of Friedman et al. 1 In one case there were not enough data to be classified. Ten cases (10.6%) had more than one risk factor for healthcareassociated acquisition. No differences between cases and controls were found with respect to the type of healthcare-related acquisition (Table 2) .
Risk factors are summarized in Table 3 . Indwelling external devices, the presence of abnormalities in the urinary or biliary tracts, and recent manipulation of the urinary, biliary, respiratory and/or gastric tracts within the last 4 weeks prior to the episode were identified more frequently among cases compared with controls. Thirty-five (16.3%) cases and 186 (43.5%) controls did not have any identifiable risk factor (P,0.0001).
Antimicrobial exposure within the 3 months prior to the episode was the most frequent risk factor identified [132/205 (64.4%) of cases versus 144/405 (35.5%) of controls, P,0.0001], (in 9 cases and 23 controls no data were available on prior exposure to antibiotics). It is noteworthy that 63/132 (47.7%) cases versus 48/144 (33%) controls had been exposed to more than one class of antibiotics (P¼0.016). The most frequently used antibiotics were penicillins with/without b-lactamase inhibitor, fluoroquinolones, cephalosporins and fosfomycin (Table 4) .
The distribution of the sources of infection is shown in Table 5 . The main source of infection was the urinary tract, accounting for almost 90% of all infections, followed by an abdominal source. Hospitalization was required in 108 cases (50.5%) and in 203 (47.4%) controls (not statistically significant). Seventeen cases (7.9%) versus 25 (5.8%) controls presented with bacteraemia (not statistically significant).
In multivariate analysis, previous use of fluoroquinolones was independently associated with the risk of AmpC-EC infection.
Healthcare-related acquisition showed a trend towards an association with AmpC-EC infection (Table 6) .
Discussion
The present cohort shows a low but not negligible prevalence of AmpC-EC in a Spanish geographical area. This is one of the largest published studies in patients infected by AmpC-EC. It sheds light on the current prevalence of AmpC-EC and the epidemiology, risk factors and clinical features of patients infected by these strains.
Previous studies reported prevalences of AmpC (mainly acquired AmpC) in E. coli ranging from 0.1% to 3.8%, showing an increasing trend in the last decade.
5, 28 -32 In our cohort, AmpC-EC infections were common in women and in the elderly One acquired AmpC-EC had genes for both CMY and DHA, and was not included in this analysis. We also found that previous use of quinolones was an independent risk factor associated with infection due to AmpC-EC. Healthcare-related acquisition was close to significance, and the OR value indicates that the risk of having an AmpC-EC infection was higher for those persons that had been receiving healthcare in an outpatient facility or had been hospitalized in the previous 90 days. Many studies have identified similar risk factors for ESBLs and AmpC-EC producers, as well as for other resistance mechanisms, in E. coli. 34 Previous antimicrobial exposure has been reported repeatedly as a risk factor for both ESBL and AmpC producers in E. coli. 14, 35, 36 Cases in the present cohort were exposed to a variety of antimicrobials with the potential for selecting AmpC-producing Enterobacteriaceae, including b-lactam/b-lactamase inhibitor combinations, fluoroquinolones and cephalosporins. In our series, fluoroquinolones were found to be the most important risk factor for selection of AmpC producers in E. coli. In Europe many authors have reported the dissemination of plasmid-mediated quinolone resistance genes in Enterobacteriaceae [qnrA -D, qnrS, aac(6 ′ )-Ib-cr and qepA], which are often associated with EBSLs or plasmid-mediated AmpC b-lactamases. One mechanism for this association is incorporation on the same plasmid as qnr and genes for ESBLs or AmpC-type b-lactamases. In 9 cases and 23 controls there was no information on previous antimicrobial use. Pascual et al.
37,38
It is noteworthy that in the present cohort close to one-fifth of AmpC-EC infections occurred among patients with no discernible risk factors. This represents a high proportion of unpredictably multiresistant infections compared with other reports. 14, 39 If the incidence of AmpC isolates keeps increasing, this epidemiological finding would have important implications for the empirical management of community-associated infection when a causal role of E. coli is suspected. On the other hand, although nosocomial outbreaks due to AmpC-producing Enterobacteriaceae have been only sporadically reported, 27, 40 the presence of this resistance mechanism in the community calls for the implementation of systems of detection and surveillance in order to implement adequate infection control measures, as plasmid-mediated genes can spread to other species.
While AmpC b-lactamases have been historically restricted to hospital-acquired isolates, the proportion of truly communityacquired cases in our cohort of AmpC-EC isolates was 42%. Few studies have provided the epidemiological data needed to distinguish community onset from true community acquisition and the reported rates have ranged from 13% to 50%. 14, 18, 19, 41 Several factors could explain the high proportion of community-acquired AmpC-EC isolates in our study: first, the study design (with strains included from both hospital and community laboratories); second, the prospective inclusion and the strict definition used for the epidemiological classification; and third, a possible dissemination of mobile genetic elements encoding acquired AmpC among a polyclonal population of E. coli in our area. A recent report showing great geographical variability in the distribution of AmpC-EC in parallel with great genetic diversity in Spain would support this contention. 27 In our cohort of AmpC-EC strains, plasmid acquisition represents the main mechanism of AmpC production, which was present in 73% of the isolates. In the few studies that have compared epidemiological and clinical features between infections due to E. coli harbouring plasmidic or hyperproduced AmpC (hAmpC), no major epidemiological or clinical differences have been identified. 34 Unfortunately, the size of our cohort precludes any meaningful comparison.
With regard to the type of AmpC b-lactamase, the CMY type (specifically CMY-2) was the most prevalent acquired AmpC, in keeping with the results of recent multicentre studies.
5,27
Interestingly enough, in our cohort CMY-type enzymes were more frequently observed among community-acquired isolates, whereas DHA types were most frequently present in the healthcare-related group. In fact, the DHA type (specifically DHA-1) was mostly seen in nursing home residents with high comorbidity, as has been reported by some, 14 but not all studies have specifically analysed a relationship among enzymes and the site of care. 29 The strengths of our study are the prospective and geographically comprehensive design, including both community and hospital patients, the availability of detailed clinical information and the presence of a control group of cephalosporin-susceptible E. coli. Our study has some limitations. Since the study was observational, the assessment of clinical outcome was based on information available from medical records. Also, we compared AmpC-EC cases in the risk factor analysis to determine risk factors that are unique to AmpC-EC cases. In doing so, we may have missed factors that otherwise would have been significant when using fully susceptible cases as controls.
To summarize, the prevalence of AmpC in E. coli remains low in our area. Traditional risk factors for multiresistant Enterobacteriaceae, such as healthcare-related acquisition and prior antimicrobial exposure, were identified in patients with infections due to AmpC-EC strains. However, high proportions of truly community-acquired isolates and patients with no identifiable risk factors were found. These epidemiological findings have important implications for the empirical management of community-associated infection when involvement of E. coli is suspected. Epidemiology of AmpC-producing E. coli
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